Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M.
Kikuchi T, et al. Among authors: hagihara h.
Liver Int. 2024 Mar 15. doi: 10.1111/liv.15907. Online ahead of print.
Liver Int. 2024.
PMID: 38488749